Nazione: Svizzera
Lingua: italiano
Fonte: Swissmedic (Swiss Agency for Therapeutic Products)
HYNIC-[D-Phe(1), Tyr(3)-octreotidi]trifluoroacetum, acidum ethylendiamini-N,N'-diaceticum
medeo AG
V09IA07
HYNIC-[D-Phe(1), Tyr(3)-octreotidi]trifluoroacetum, acidum ethylendiamini-N,N'-diaceticum
Markierungsbesteck
I) Durchstechflasche 1: HYNIC-[D-Phe(1), Tyr(3)-octreotidi]trifluoroacetum 16 µg, tricinum, stannosi chloridum dihydricum, mannitolum, natrii hydroxidum aut acidum hydrochloridum, pro vitro. II) Durchstechflasche 2: acidum ethylendiamini-N,N'-diaceticum 10 mg, dinatrii phosphas dodecahydricus, natrii hydroxidum, acidum hydrochloridum aut natrii hydroxidum, pro vitro corresp. natrium 3.9 mg.
A
Radiopharmazeutika
SPECT/CT-Rappresentazione rezeptortragender PEC e karzinoider Tumori
zugelassen
2018-04-25